PB 135 of 2024 National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024 I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following determination. Dated 28 November 2024 Eden Simon Acting Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health and Aged Care Contents 1 Name 2 Commencement 3 Authority 4 Schedules Schedule 1—Amendments commencing 1 December 2024 National Health (Minimum Stockholding) Determination 2023 1 Name (1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024. (2) This instrument may also be cited as PB 135 of 2024. 2 Commencement 1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms. Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table 1 December 2024. 1 December 2024 2. Schedule 1 1 December 2024. 1 December 2024 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument. 3 Authority This instrument is made under subsection 99AEKC(2) of the National Health Act 1953. 4 Schedules Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms. Schedule 1—Amendments commencing 1 December 2024 National Health (Minimum Stockholding) Determination 2023 1 Schedule 1 (table) After: Acarbose Tablet 50 mg Oral GLYBOSAY 2 months stock by reference to usual demand insert: Aciclovir Tablet 200 mg Oral Aciclovir APOTEX 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together Aciclovir Tablet 200 mg Oral ARX-ACICLOVIR 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together Aciclovir Tablet 800 mg Oral Aciclovir APOTEX 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together Aciclovir Tablet 800 mg Oral ARX-ACICLOVIR 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together 2 Schedule 1 (table) After: Allopurinol Tablet 100 mg Oral Allosig 3 months stock by reference to usual demand insert: Allopurinol Tablet 100 mg Oral APO-ALLOPURINOL 4 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together 3 Schedule 1 (table) After: Allopurinol Tablet 100 mg Oral Zyloprim 3 months stock by reference to usual demand insert: Allopurinol Tablet 300 mg Oral APO-ALLOPURINOL 6 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together 4 Schedule 1 (table) After: Amitriptyline Tablet containing amitriptyline hydrochloride 50 mg Oral ENTRIP (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand insert: Amlodipine Tablet 5 mg (as besilate) Oral APX-AMLODIPINE 6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together 5 Schedule 1 (table) After: Atomoxetine Capsule 80 mg (as hydrochloride) Oral APO‑Atomoxetine 3 months stock by reference to usual demand insert: Azacitidine Powder for injection 100 mg Injection Azacitidine-Teva between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand 6 Schedule 1 (table) After: Bisoprolol Tablet containing bisoprolol fumarate 5 mg Oral Cipla Bisoprolol between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand insert: Bivalirudin Powder for I.V. injection 250 mg (as trifluoroacetate) Injection Bivalirudin APOTEX 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together Bivalirudin Powder for I.V. injection 250 mg (as trifluoroacetate) Injection BIVALIRUDIN ARX 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together 7 Schedule 1 (table) After: Carmellose with glycerin Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL Application to the Eye Optive between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand insert: Cefazolin Powder for injection 1 g (as sodium) Injection Cefazolin-AFT between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand 8 Schedule 1 (table) Omit: Cefepime Powder for injection 1 g (as hydrochloride) Injection Cefepime Kabi between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand Cefepime Powder for injection 2 g (as hydrochloride) Injection Cefepime Kabi between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand 9 Schedule 1 (table) After: Ciclosporin Capsule 100 mg Oral APO‑Ciclosporin 2.5 months stock by reference to usual demand insert: Ciclosporin Capsule 100 mg Oral Cyclosporin Sandoz between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand 10 Schedule 1 (table) After: Ciclosporin Capsule 25 mg Oral APO‑Ciclosporin 3 months stock by reference to usual demand insert: Ciclosporin Capsule 25 mg Oral Cyclosporin Sandoz between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand 11 Schedule 1 (table) After: Ciclosporin Capsule 50 mg Oral APO‑Ciclosporin 3 months stock by reference to usual demand insert: Ciclosporin Capsule 50 mg Oral Cyclosporin Sandoz between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand 12 Schedule 1 (table) After: Clonazepam Oral liquid 2.5 mg per mL, 10 mL Oral Rivotril 6 months stock by reference to usual PBS demand insert: Clopidogrel with aspirin Tablet 75 mg (as hydrogen sulfate)-100 mg Oral Clopidogrel Winthrop plus aspirin between 1 December 2024 and 31 March 2025—0 months stock by reference to usual demand 13 Schedule 1 (table) After: Entecavir Tablet 0.5 mg (as monohydrate) Oral Entecavir Viatris after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together insert: Entecavir Tablet 1 mg (as monohydrate) Oral Entecavir Viatris after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together 14 Schedule 1 (table) Omit: Epoprostenol Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL Injection Flolan between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand Epoprostenol Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL Injection Flolan between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand 15 Schedule 1 (table) After: Fentanyl Transdermal patch 8.4 mg Transdermal APO‑Fentanyl 3 months stock by reference to usual demand insert: Fluconazole Capsule 200 mg Oral APO-Fluconazole 4 months stock by reference to usual demand of both Fluconazole APOTEX and APO-Fluconazole added together 16 Schedule 1 (table) Omit: Furosemide Oral solution 10 mg per ml, 30 ml Oral Lasix (a) between 1 November 2024 and 31 March 2024—4 months stock by reference to usual PBS demand (b) after 31 March 2024—6 months stock by reference to usual PBS demand substitute: Furosemide Oral solution 10 mg per ml, 30 ml Oral Lasix (a) between 1 November 2024 and 31 March 2025—4 months stock by reference to usual PBS demand (b) after 31 March 2025—6 months stock by reference to usual PBS demand 17 Schedule 1 (table) After: Gabapentin Capsule 400 mg Oral GAPENTIN 3 months stock by reference to usual demand insert: Gabapentin Tablet 600 mg Oral APX-GABAPENTIN 4 months stock by reference to usual demand of both Gabapentin APOTEX and APX-GABAPENTIN added together 18 Schedule 1 (table) After: Galantamine Capsule (prolonged release) 8 mg (as hydrobromide) Oral Gamine XR 3 months stock by reference to usual demand insert: Glimepiride Tablet 1 mg Oral ARX-GLIMEPIRIDE 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together Glimepiride Tablet 1 mg Oral Glimepiride APOTEX 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together Glimepiride Tablet 2 mg Oral ARX-GLIMEPIRIDE 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together Glimepiride Tablet 2 mg Oral Glimepiride APOTEX 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together Glimepiride Tablet 3 mg Oral ARX-GLIMEPIRIDE 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together Glimepiride Tablet 3 mg Oral Glimepiride APOTEX 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together Glimepiride Tablet 4 mg Oral ARX-GLIMEPIRIDE 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together Glimepiride Tablet 4 mg Oral Glimepiride APOTEX 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together 19 Schedule 1 (table) Omit: Imatinib Capsule 100 mg (as mesilate) Oral Imatinib‑APOTEX 3 months stock by reference to usual demand Imatinib Capsule 400 mg (as mesilate) Oral Imatinib‑APOTEX 3 months stock by reference to usual demand 20 Schedule 1 (table) After: Hypromellose with carbomer 980 Ocular lubricating gel 3 mg-2 mg per g, 10 g Application to the Eye HPMC PAA between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand insert: Imatinib Capsule 100 mg (as mesilate) Oral ARX-IMATINIB 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together Imatinib Capsule 100 mg (as mesilate) Oral Imatinib-APOTEX 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together Imatinib Capsule 400 mg (as mesilate) Oral ARX-IMATINIB 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together Imatinib Capsule 400 mg (as mesilate) Oral Imatinib-APOTEX 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together 21 Schedule 1 (table) After: Irbesartan with hydrochlorothiazide Tablet 150 mg-12.5 mg Oral AVSARTAN HCT 150/12.5 4 months stock by reference to usual demand insert: Iron polymaltose complex Injection 100 mg (iron) in 2 mL Injection Ferrosig between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand 22 Schedule 1 (table) After: Latanoprost with timolol Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL Application to the Eye APO‑Latanoprost/Timolol 0.05/5 2.5 months stock by reference to usual demand insert: Leflunomide Tablet 10 mg Oral APO-LEFLUNOMIDE 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together Leflunomide Tablet 20 mg Oral APO-LEFLUNOMIDE 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together Lercanidipine Tablet containing lercanidipine hydrochloride 10 mg Oral ARX-LERCANIDIPINE 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together Lercanidipine Tablet containing lercanidipine hydrochloride 20 mg Oral ARX-LERCANIDIPINE 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together Letrozole Tablet 2.5 mg Oral ARX-LETROZOLE 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together Letrozole Tablet 2.5 mg Oral Letrozole APOTEX 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together 23 Schedule 1 (table) After: Milk protein and fat formula with vitamins and minerals -- carbohydrate free Oral powder 225 g (Carbohydrate Free Mixture) Oral Carbohydrate Free Mixture 6 months stock by reference to usual PBS demand insert: Mirtazapine Tablet 45 mg Oral NOUMED MIRTAZAPINE between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand 24 Schedule 1 (table) After: Modafinil Tablet 100 mg Oral Modafin 3 months stock by reference to usual demand insert: Modafinil Tablet 100 mg Oral Modafinil Viatris after 28 February 2025— 4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together Montelukast Tablet, chewable, 4 mg (as sodium) Oral APX-Montelukast 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together Montelukast Tablet, chewable, 5 mg (as sodium) Oral APX-Montelukast 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together Mycophenolic acid Tablet containing mycophenolate mofetil 500 mg Oral ARX-MYCOPHENOLATE 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together Mycophenolic acid Tablet containing mycophenolate mofetil 500 mg Oral Mycophenolate APOTEX 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together 25 Schedule 1 (table) After: Nortriptyline Tablet 25 mg (as hydrochloride) Oral NortriTABS 25 mg between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand insert: Olanzapine Tablet 10 mg Oral APO-OLANZAPINE 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together 26 Schedule 1 (table) After: Olanzapine Tablet 15 mg (orally disintegrating) Oral Zypine ODT (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together. insert: Olanzapine Tablet 2.5 mg Oral APO-OLANZAPINE 6 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together 27 Schedule 1 (table) After: Olanzapine Tablet 20 mg (orally disintegrating) Oral Zypine ODT (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together insert: Olanzapine Tablet 5 mg Oral APO-OLANZAPINE 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together 28 Schedule 1 (table) After: Olanzapine Tablet 5 mg (orally disintegrating) Oral Zypine ODT (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together insert: Olanzapine Tablet 7.5 mg Oral APO-OLANZAPINE 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together 29 Schedule 1 (table) After: Olmesartan Tablet containing olmesartan medoxomil 40 mg Oral OLMERTAN (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand insert: Olmesartan with amlodipine Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) Oral APO-OLMESARTAN/AMLODIPINE 20/5 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 20/5 mg added together Olmesartan with amlodipine Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) Oral APO-OLMESARTAN/AMLODIPINE 40/10 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/10 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/10 added together Olmesartan with amlodipine Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) Oral APO-OLMESARTAN/AMLODIPINE 40/5 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/5 mg added together 30 Schedule 1 (table) After: Pantoprazole Sachet containing granules 40 mg (as sodium sesquihydrate) Oral Somac 4 months stock by reference to usual PBS demand insert: Pantoprazole Tablet (enteric coated) 20 mg (as sodium sesquihydrate) Oral APX-PANTOPRAZOLE 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together 31 Schedule 1 (table) After: Pantoprazole Tablet (enteric coated) 20 mg (as sodium sesquihydrate) Oral APO‑Pantoprazole (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand insert: Pantoprazole Tablet (enteric coated) 40 mg (as sodium sesquihydrate) Oral APX-PANTOPRAZOLE 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together 32 Schedule 1 (table) After: Permethrin Cream 50 mg per g, 30 g Application Lyclear 6 months stock by reference to usual PBS demand insert: Phenoxymethylpenicillin Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL Oral Phenoxymethylpenicillin-AFT between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand 33 Schedule 1 (table) After: Pimecrolimus Cream 10 mg per g, 15 g Application Elidel 6 months stock by reference to usual PBS demand insert: Pioglitazone Tablet 15 mg (as hydrochloride) Oral APOTEX-Pioglitazone 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together Pioglitazone Tablet 15 mg (as hydrochloride) Oral ARX-PIOGLITAZONE 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together Pioglitazone Tablet 30 mg (as hydrochloride) Oral APOTEX-Pioglitazone 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together Pioglitazone Tablet 30 mg (as hydrochloride) Oral ARX-PIOGLITAZONE 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together Pioglitazone Tablet 45 mg (as hydrochloride) Oral APOTEX-Pioglitazone 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together Pioglitazone Tablet 45 mg (as hydrochloride) Oral ARX-PIOGLITAZONE 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together 34 Schedule 1 (table) After: Protein hydrolysate formula with medium chain triglycerides Oral powder 450 g (Aptamil Gold+ Pepti-Junior) Oral Aptamil Gold+ Pepti-Junior 6 months stock by reference to usual PBS demand insert: Quetiapine Tablet 100 mg (as fumarate) Oral APX-QUETIAPINE 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together Quetiapine Tablet 200 mg (as fumarate) Oral APX-QUETIAPINE 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together Quetiapine Tablet 25 mg (as fumarate) Oral APX-QUETIAPINE 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together Quetiapine Tablet 300 mg (as fumarate) Oral APX-QUETIAPINE 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together 35 Schedule 1 (table) After: Risperidone Tablet 3 mg Oral Rispa 3 months stock by reference to usual demand insert: Rizatriptan Tablet (orally disintegrating) 10 mg (as benzoate) Oral APO-RIZATRIPTAN ODT 4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO-RIZATRIPTAN ODT added together Rosuvastatin Tablet 10 mg (as calcium) Oral APO-Rosuvastatin 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-Rosuvastatin added together Rosuvastatin Tablet 20 mg (as calcium) Oral APO-ROSUVASTATIN 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together Rosuvastatin Tablet 40 mg (as calcium) Oral APO-ROSUVASTATIN 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together Rosuvastatin Tablet 5 mg (as calcium) Oral APO-ROSUVASTATIN 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together 36 Schedule 1 (table) Omit: Salbutamol Nebuliser solution 2.5 mg (as sulfate) in 2.5 ml single dose units, 30 Inhalation Salbutamol Cipla between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand. Salbutamol Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30 Inhalation Salbutamol Cipla between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand. 37 Schedule 1 (table) After: Sertraline Tablet 50 mg (as hydrochloride) Oral NOUMED SERTRALINE between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand insert: Sevelamer Tablet containing sevelamer carbonate 800 mg Oral ARX-SEVELAMER 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together Sevelamer Tablet containing sevelamer carbonate 800 mg Oral Sevelamer Apotex 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together 38 Schedule 1 (table) After: Tacrolimus Capsule 5 mg Oral Tacrograf 3 months stock by reference to usual demand insert: Telmisartan Tablet 40 mg Oral NOUMED TELMISARTAN between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand 39 Schedule 1 (table) After: Temazepam Tablet 10 mg Oral APO‑Temazepam 2.5 months stock by reference to usual demand insert: Tenofovir Tablet containing tenofovir disoproxil fumarate 300 mg Oral Tenofovir APOTEX 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together Tenofovir Tablet containing tenofovir disoproxil fumarate 300 mg Oral Tenofovir ARX 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together 40 Schedule 1 (table) Omit: Tenofovir with emtricitabine Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg Oral Tenofovir/Emtricitabine 300/200 APOTEX 3 months stock by reference to usual demand 41 Schedule 1 (table) After: Tenofovir Tablet containing tenofovir disoproxil maleate 300 mg Oral Tenofovir Disoproxil Viatris after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together insert: Tenofovir with emtricitabine Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg Oral Tenofovir/Emtricitabine 300/200 APOTEX 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together Tenofovir with emtricitabine Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg Oral TENOFOVIR/EMTRICITABINE 300/200 ARX 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together 42 Schedule 1 (table) After: Valproic acid Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL Oral Epilim Syrup 6 months stock by reference to usual PBS demand insert: Valproic acid Tablet (enteric coated) containing sodium valproate 200 mg Oral APO-Sodium Valproate between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 200 mg Oral Epilim EC between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 200 mg Oral Sodium Valproate Sandoz between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 200 mg Oral Valprease 200 between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 200 mg Oral Valpro EC 200 between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 200 mg Oral Valproate Winthrop EC 200 between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 500 mg Oral APO-Sodium Valproate between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 500 mg Oral Epilim EC between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 500 mg Oral Sodium Valproate Sandoz between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 500 mg Oral Valprease 500 between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 500 mg Oral Valpro EC 500 between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand Valproic acid Tablet (enteric coated) containing sodium valproate 500 mg Oral Valproate Winthrop EC 500 between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand 43 Schedule 1 (table) Omit: Vancomycin Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) Injection Vancomycin Viatris after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together substitute: Vancomycin Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) Injection Vancomycin Viatris 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together 44 Schedule 1 (table) Omit: Vancomycin Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) Injection Vancomycin Viatris after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together substitute: Vancomycin Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) Injection Vancomycin Viatris 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together